Primary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children
ABSTRACT The dual epidemic of human immunodeficiency virus (HIV) and tuberculosis is a major cause of sickness and death in sub-Saharan Africa. We conducted a double-blind, randomized, placebo-controlled trial of preexposure isoniazid prophylaxis against tuberculosis in HIV-infected children and uninfected children exposed to HIV during the perinatal period.
We randomly assigned 548 HIV-infected and 804 HIV-uninfected infants (91 to 120 days of age) to isoniazid (10 to 20 mg per kilogram of body weight per day) or matching placebo for 96 weeks. All patients received bacille Calmette-Guérin (BCG) vaccination against tuberculosis within 30 days after birth. HIV-infected children had access to antiretroviral therapy. The primary outcome measures were tuberculosis disease and death in HIV-infected children and latent tuberculosis infection, tuberculosis disease, and death in HIV-uninfected children within 96 to 108 weeks after randomization.
Antiretroviral therapy was initiated in 98.9% of HIV-infected children during the study. Among HIV-infected children, protocol-defined tuberculosis or death occurred in 52 children (19.0%) in the isoniazid group and 53 (19.3%) in the placebo group (P=0.93). Among HIV-uninfected children, there was no significant difference in the combined incidence of tuberculosis infection, tuberculosis disease, or death between the isoniazid group (39 children, 10%) and the placebo group (45 children, 11%; P=0.44). The rate of tuberculosis was 121 cases per 1000 child-years (95% confidence interval [CI], 95 to 153) among HIV-infected children as compared with 41 per 1000 child-years (95% CI, 31 to 52) among HIV-uninfected children. There were no significant differences in clinical or severe laboratory toxic effects between treatment groups.
Primary isoniazid prophylaxis did not improve tuberculosis-disease-free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine. Despite access to antiretroviral therapy, the burden of tuberculosis remained high among HIV-infected children. (Funded by the National Institutes of Health and Secure the Future; ClinicalTrials.gov number, NCT00080119.).
Full-textDOI: · Available from: Shabir A Madhi, Aug 13, 2015
- [Show abstract] [Hide abstract]
ABSTRACT: ARV TDM may improve patient outcome due to the clinical consequences of therapeutic failure, marked interindividual variability in ARV plasma concentrations, and data supporting concentration/response relationships. 3 Unlike non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) are not considered suitable candidates for ARV TDM. The NRTI intracellular triphosphate anabolite is the active moiety and is only weakly correlated with parent plasma concentrations. 4 However, due to long half-lives of NNRTIs, it may be difficult to evaluate cART adherence using NNRTI steady-state concentrations ( Fig. 1 ). The NRTI lamivudine (3TC) has suitable pharmacokinetic (PK) properties (Tmax = 0.9h (SD 0.41h), half-life = 8.41h (SD 1.46)) 5 to assess dosing history up to 36 hours post-dose. Additionally, 3TC pharmacokinetics is unaltered by concomitant anti-tuberculosis treatment, a common opportunistic infection in our population. Routine blood sampling at ARV-outpatient clinics is seldom pre-dose/trough concentrations and acceptable minimum single time-point concentration data during the whole 12-hour NVP and 3TC dosing intervals were unavailable. The aim of the analyses was to use a population modeling approach to obtain concentration "cut-off" values (e.g. the lower limit of the 95% prediction intervals) for NVP and 3TC concentrations to assess adherence to cART.
- New England Journal of Medicine 07/2011; 365(1):79-81. DOI:10.1056/NEJMe1105555 · 54.42 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: In recent years, several notable modifications have occurred in the management of TB infection and disease in children. First, we review new data related to infection, including alternative regimens for the treatment of latent TB, management of drug-resistant infection and preventive therapy in the context of HIV infection. Next, we summarize updated WHO guidelines for the treatment of TB in children, explore issues specific to the management of disease in HIV-infected children, and retreatment of TB, and review pediatric recommendations for the management of drug-resistant TB. Finally, we conclude with a discussion of adjunctive therapy and new drugs in development.Expert Review of Anticancer Therapy 12/2011; 9(12):1157-68. DOI:10.1586/eri.11.144 · 3.06 Impact Factor